Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00949910 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00949910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00949910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2004
Completion date
April 30, 2009
Enrollment
6,586 (actual)
Sites
543

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer